Skip to main content

April 2016

 

 

academics

 

Clinical research courses

Recruitment for M.Pharm candidates as faculties (13 posts) at Tatyasaheb Kore College of Pharmacy

All progressive organizations are an outcome of the dreams, ideas and creativity of its leader(s). Shree Warana Vibhag Shikshan Mandal was established in 1964, by great visionary Late Hon’ble Shree V. A. alias Tatyasaheb Kore with endeavor of making education accessible to the deprived and deserving. Under the dynamic guidance of Hon’ble Shri. Vinayraoji Kore, Chairman, SWVSM; it presently caters primary to P.G. courses with well furnished hostels and staff quarters in a sprawling campus of 100 acres. Under the aegis of this society Tatyasaheb Kore College of Pharmacy was born in the year 2004.

Applications are invited from eligible candidates for the following posts:

Post: Professor, Associate Professor, Assistant Professor

Opening for Pharmacist (2 Posts) in ARRI - govt job

The Central Council for Research in Ayurvedic Sciences (CCRAS) is an autonomous body of the Ministry of AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy), Government of India. It is an apex body in India for the formulation, co-ordination, development and promotion of research on scientific lines in Ayurveda and Sowa-Rigpa system of medicine.

The increasing incidence of Alzheimer's disease (AD), improving diagnostic technologies and the prospect of new therapies are driving the global AD market. BCC Research reveals in its new report the need for effective treatments has become more urgent, especially given the recurrent failure of several prominent disease-modifying agents in late-stage development.

Opportunity to work as Clinical Data Coder I in Parexel

PAREXEL has supported the Bio-Tech and Pharmaceutical industries in helping the development of new drugs and treatments on a global basis. As a leading global biopharmaceutical service provider, they supply knowledge-based contract research, medical communications and consulting services across a broad range of therapeutic areas to the worldwide pharmaceutical, biotechnology and medical device industries. They have helped over 800 clients to develop and launch some of the most important drugs and devices of our time-helping people live better and healthier lives everywhere in the world. Headquartered near Boston, Massachusetts, PAREXEL operates in more than 50 countries around the world.

Post: Clinical Data Coder I

Job for Research Associate at Naresh Hospital and Research center

Naresh Hospital and Research center; Serving for 33 years in healthcare sector. Besides we are involved in clinical and pharmaceutical research. Approved center for Tilak Maharashtra University. Pune in Delhi NCR region.

Post: Research Associate

The U.S. Food and Drug Administration approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with CLL.

Career for Teaching positions at St. Ann’s College of Pharmacy

St. Ann’s College of Pharmacy came into existence in the year 2007 and is located at Nayunipalli - 6 kms. from Chirala township and is an ideal location for an educational institute with its tranquil environment, free from noise and air pollution. The institute is approved by All India Council for Technical Education (AICTE), New Delhi and is affiliated to Jawaharlal Nehru Technological University, Kakinada.

Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) announced that one of its wholly owned subsidiaries has received approval from USFDA for its New Drug Application (NDA) related to BromSite™ (bromfenac ophthalmic solution) 0.075% for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. BromSite™ is the first non-steroidal anti-inflammatory drug (NSAID) approved by the USFDA to prevent pain and treat inflammation in the eye for patients undergoing cataract surgery; other NSAIDs in this class are currently indicated for the treatment of inflammation and reduction of pain.

The Medicines Company announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation to the investigational agent CARBAVANCE® (meropenem-vaborbactam) for the treatment of complicated urinary tract infections (cUTI). CARBAVANCE is the combination of the carbapenem antibiotic, meropenem, with the novel beta-lactamase inhibitor, vaborbactam (formerly known as RPX7009), that is being developed for the treatment of gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae (CRE).